TNBC patients with mutations in BRCA1 and TP53 experienced worse relapse-free survival (RFS) in breast cancer, illustrating the importance of mutation-specific ctDNA profiling for prognostic evaluation [62]. The gene discussed is TP53; the disease is breast carcinoma.